Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis

Since the demonstration that poor prednisone response was associated with an increased relapse risk, early evaluation of in vivo tumor burden reduction has been established as the most powerful pro...

[1]  R. Itzykson,et al.  New Treatment Options for Acute Myeloid Leukemia in 2019 , 2019, Current Oncology Reports.

[2]  Torsten Haferlach,et al.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.

[3]  M. Carroll,et al.  Dexamethasone in hyperleukocytic acute myeloid leukemia , 2018, Haematologica.

[4]  P. Qiu,et al.  Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy , 2016, American journal of hematology.

[5]  H. Dombret,et al.  Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia , 2016, Leukemia & lymphoma.

[6]  G. Ehninger,et al.  How I treat hyperleukocytosis in acute myeloid leukemia. , 2015, Blood.

[7]  J. Beyene,et al.  Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. , 2014, Leukemia research.

[8]  M. Tallman,et al.  How I treat hematologic emergencies in adults with acute leukemia. , 2012, Blood.

[9]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[10]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[11]  F. Mannelli,et al.  Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. , 2008, Blood.

[12]  A. Schechter,et al.  Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. , 2006, Blood.

[13]  J. Harbott,et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.

[14]  R. E. Cunningham,et al.  Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin. , 1981, Cancer research.

[15]  S. Chevret,et al.  Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.